Please login to the form below

Not currently logged in
Email:
Password:

Bone Therapeutics strengthens board with new chairman

Jean Stéphenne joins the cell therapy company from TiGenix

Belgian biotechnology company Bone Therapeutics has appointed Jean Stéphenne as its new chairman of the board of directors, succeeding Steve Swinson in the process.

Stéphenne’s career history has seen him serve in senior leadership roles at several biotechnology and pharmaceutical companies, most recently as chairman of TiGenix.

He has also been a member of the corporate executive team for GlaxoSmithKline and chief executive officer of GSK Biologicals (now GSK Vaccines).

Thomas Lienard, chief executive officer of Bone Therapeutics, said: “Stéphenne has unparalleled experience in drug development and building innovative life science companies and is highly regarded within the sector.

“He will be a valuable addition to an already strong board as we advance our allogeneic cell therapy platform through clinical studies.”

26th February 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics